Table 2.
The Ratio of Women's Participation in Clinical Trials for the Indicated Disease Relative to the Estimated Proportion of Women in the Disease Population (PPR) by Therapeutic Grouping
| Therapeutic grouping (no. of new drugsa) | Mean PPR | Standard error | 95% confidence interval |
|---|---|---|---|
| Anti-infectives (3) | 1.13 | 0.13 | 0.56 to 1.71 |
| Antivirals (8) | 0.99 | 0.06 | 0.84 to 1.14 |
| Cardiovascular/renal (8) | 1.05 | 0.17 | 0.65 to 1.45 |
| Dermatology (7) | 0.80 | 0.11 | 0.53 to 1.07 |
| Gastroenterology/inborn errors (8) | 1.11 | 0.09 | 0.90 to 1.32 |
| Metabolism/endocrinology (8) | 1.03 | 0.03 | 0.97 to 1.08 |
| Neurology (3) | 0.97 | 0.07 | 0.68 to 1.25 |
| Oncology/nononcology hematology (34) | 1.10 | 0.06 | 0.98 to 1.22 |
| Psychiatry (6) | 0.78 | 0.08 | 0.57 to 1.00 |
| Pulmonary/allergy/rheumatology (9) | 0.72 | 0.10 | 0.49 to 0.95 |
| Special pathogens (1) | 1.00 | N/A | N/A |
This only includes new drugs with indications for which estimated prevalence or incidence data were found and, therefore, a PPR could be calculated. Thus, there was no PPR available for the therapeutic groupings, “Anesthesia/Analgesia” and “Medical Imaging.”
a
The sum of the number of new drugs (n = 95) is greater than the number of drugs for which estimated prevalence or incidence was found (n = 82) because several drugs have multiple indications and, thus, were captured more than once.